Loading...
•
Sep 30, 2024
Xenon Pharmaceuticals Q3 2024 Earnings Report
Xenon Pharmaceuticals reported financial results for Q3 2024 and provided a business update.
Key Takeaways
Xenon Pharmaceuticals reported a net loss of $62.8 million for the quarter ended September 30, 2024, compared to a net loss of $48.5 million for the same period in 2023. As of September 30, 2024, cash and cash equivalents and marketable securities were $803.3 million.
Phase 3 epilepsy program advancing with X-TOLE2 topline FOS data anticipated in H2 2025.
Long-term azetukalner results from X-TOLE open-label extension study in FOS to be presented at AES.
Phase 3 MDD program on track with X-NOVA2 study expected to initiate by year-end.
Expanding ion channel portfolio includes multiple candidates advancing towards IND filings in 2025.
Forward Guidance
Xenon anticipates having sufficient cash to fund operations into 2027.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...